Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 2,738 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neuroendocrine Tumours Clear all
Terminated Phase 1 Interventional

A Phase 1 Study of [225Ac]-FPI-1434 Injection

NCT03746431
View directory record Official record
Conditions
Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Adrenocortical Carcinoma, Uveal Melanoma
Interventions
[111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion, [225Ac]-FPI-1434 Injection single-dose
Drug · Biological
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 15, 2026, 10:19 PM EDT
Completed Phase 1Phase 2 Interventional

Study of PI-88 in Patients With Advanced Melanoma

NCT00068172
View directory record Official record
Conditions
Melanoma
Interventions
PI-88
Drug
Lead sponsor
Cellxpert Biotechnology Corp.
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 15, 2026, 10:19 PM EDT
Active, not recruiting Phase 2 Interventional

Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients

NCT05153772
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
AlphaMedix
Drug
Lead sponsor
Orano Med LLC
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
4
States / cities
Denver, Colorado • Tampa, Florida • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 15, 2026, 10:19 PM EDT
Completed Phase 1 Interventional

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

NCT01005472
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
sunitinib malate, temozolomide
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 15, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma

NCT00610857
View directory record Official record
Conditions
Melanoma
Interventions
Anti-CTLA4 monoclonal antibody and HDI
Drug
Lead sponsor
Ahmad Tarhini
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 15, 2026, 10:19 PM EDT
Active, not recruiting No phase listed Observational

MElanoma Research Lymph Node Prediction Implementation National_001

NCT04759781
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
SkylineDx
Industry
Eligibility
18 Years and older
Enrollment
1,820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 15, 2026, 10:19 PM EDT
Withdrawn Phase 1 Interventional

A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma

NCT00661336
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
buthionine sulfoximine, melphalan, microarray analysis, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2015 · Synced Oct 15, 2026, 10:19 PM EDT
Terminated Phase 2 Interventional

Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma

NCT01026051
View directory record Official record
Conditions
Stage III Melanoma, Stage IV Melanoma
Interventions
MKC1106-MT
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Stuart, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Oct 15, 2026, 10:19 PM EDT
Terminated Phase 1Phase 2 Interventional

Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma

NCT00358319
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Karenitecin, Valproic Acid
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 15, 2026, 10:19 PM EDT
Completed Phase 1 Interventional

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

NCT01076530
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Extra-adrenal Paraganglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions
vorinostat, temozolomide, diagnostic laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
7
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 15, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

NCT01767792
View directory record Official record
Conditions
Neurofibromatosis Type 2, Progressive Vestibular Schwannomas
Interventions
Bevacizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 15, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tasisulam in Treating Participants With Malignant Melanoma

NCT00383292
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
tasisulam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Lakeland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 15, 2026, 10:19 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

NCT00658892
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
B7-DC cross-linking antibody rHIgM12B7, flow cytometry, immunologic technique, laboratory biomarker analysis
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 15, 2026, 10:19 PM EDT
Terminated Phase 3 Interventional Results available

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

NCT02967692
View directory record Official record
Conditions
Melanoma
Interventions
Spartalizumab, Placebo, Dabrafenib, Trametinib
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
12
States / cities
Encinitas, California • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 15, 2026, 10:19 PM EDT
Not listed Phase 1 Interventional

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

NCT03098160
View directory record Official record
Conditions
Pancreatic Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Prostate Cancer
Interventions
Evofosfamide, Ipilimumab
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Oct 15, 2026, 10:19 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

NCT06660420
View directory record Official record
Conditions
Phase 1, Recurrent Melanoma, Refractory Melanoma
Interventions
Cyclophosphamide, Fludarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 15, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560

NCT04351373
View directory record Official record
Conditions
Vestibular Schwannoma
Interventions
Fluorescein Sodium, YELLOW560 filter
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 15, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

Lovastatin in Treating Patients At High Risk of Melanoma

NCT00462280
View directory record Official record
Conditions
Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
Interventions
lovastatin, placebo, biopsy, laboratory biomarker analysis
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Orange, California • Tampa, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 15, 2026, 10:19 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells

NCT00482105
View directory record Official record
Conditions
Melanoma
Interventions
EGIR Tape
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 15, 2026, 10:19 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

NCT03470922
View directory record Official record
Conditions
Melanoma
Interventions
Relatlimab, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • San Luis Obispo, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 15, 2026, 10:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Risk Information and Skin-cancer Education for Undergraduate Prevention

NCT03979872
View directory record Official record
Conditions
Melanoma, Young Adult
Interventions
MC1R Genetic Testing, Skin Cancer Education, UV Photo
Diagnostic Test · Other · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 15, 2026, 10:19 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

NCT01628913
View directory record Official record
Conditions
Pancreatic Neuroendocrine Tumors (pNET)
Interventions
BEZ235, Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 15, 2026, 10:19 PM EDT
Completed Early Phase 1 Interventional

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

NCT04581382
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Pembrolizumab, Radiation Therapy, Therapeutic Exchange Plasma, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging
Biological · Radiation · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 15, 2026, 10:19 PM EDT
Completed Not applicable Interventional Results available

Treatment With Intravitreal Avastin for Large Uveal Melanomas

NCT00596362
View directory record Official record
Conditions
Uveal Melanoma
Interventions
AVASTIN
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2016 · Synced Oct 15, 2026, 10:19 PM EDT